The company's shares are trading about 18% higher intra-day, at 7.8 cents.
Showing 25 of 1069
Since 2011, ClearVue has focused on the development of specialty glass coating.
Oliver’s listed on the ASX on 21 June 2017 after raising $15 million in an IPO.
Up to $750,000 of contract value to be booked in calendar year 2018.
The two-year contract involves supply of the full suite of MyHealth1st products to the fast -growing network
The company's video analysis software can monitor for people not abiding by parking rules.
Shares have traded up 47% or 1.9 cents higher to 6 cents per share.
The new cryptocurrency mining site is expected to be operational within three months.
The non-exclusive distribution licence covers 14 countries in southern Africa.
Graphite produced in the Hazer Process could be a low-cost alternative.
Clinical studies in Australia have indicated that PainChek is a valid and reliable pain assessment tool.
Shares in the company were up 17.3% or 31 cents intraday to $2.10 per share.
Patersons' price target of $1.15 implies upside of 130% relative to XTEK's current share price.
Shares in the company are trading up 36% today, last priced at 2.6 cents.
Other listed childcare players include Think Childcare (ASX:TNK) and Mayfield Childcare (ASX:MFD).
Based in Atlanta, partner N3 serves a global client base, which in addition to Microsoft, includes SAP, IBM and Cisco.
Management is hoping that completion of the workshops may result in the development of a long-term relationship.
The company has a healthy contract revenue pipeline of $41 million.
Pain often goes undetected and untreated in people with dementia.
Providing further momentum in 2019 will be the launch of new products pitched at the cycling commuter market.
The new features for the UGC legal rights platform will be completed this month.
The LIC ended up raising more than double its maximum in the IPO.
Funds raised will be put towards battery sales and business development.
Sales for the March quarter were about 40% higher than the December quarter.
Simon Rushton is now a non-executive director of the company which is commercialising the Hazer Process.